Medication therapy management in community pharmacy practice: Core elements of an MTM service (Version 1.0)

Journal of the American Pharmacists Association

Volumn 45, Issue 5, 2005, Pages 573-579

  Burns, Anne ^a  

^a AMERICAN PHARMACISTS ASSOCIATION   (United States)

Author keywords

Community and ambulatory practice; Medicare; Medication therapy management; Pharmaceutical care

Indexed keywords

HEALTH CARE; HEALTH CARE ORGANIZATION; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH SERVICE; HUMAN; INTERPERSONAL COMMUNICATION; MEDICARE; MEDICATION THERAPY MANAGEMENT; PATIENT CARE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACY; PUBLIC HEALTH; REVIEW; ARTICLE; DRUG INDUSTRY; DRUG THERAPY; HEALTH INSURANCE; NONBIOLOGICAL MODEL; PATIENT CARE PLANNING; TREATMENT OUTCOME;

COMMUNITY PHARMACY SERVICES; DRUG INDUSTRY; DRUG THERAPY; INSURANCE, HEALTH; MODELS, ORGANIZATIONAL; PATIENT CARE PLANNING; SOCIETIES, PHARMACEUTICAL; TREATMENT OUTCOME;

EID: 31544442989     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/1544345055001256     Document Type: Editorial

References (22)

1. Bootman JL, Johnson JA. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155:1949-56.
2. Garrett D, Bluml B. Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005;45:130-7.
3. Cranor CW, Bunting BA, Christensen DB. The Ashevilie project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:173-90.
4. Chrischilles EA, Carter BL, Lund BC, et al. Evaluation of the Iowa Medicaid pharmaceutical case management program. J Am Pharm Assoc. 2004;44:337-49.
5. United States Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Final Rule; 42 CFR Parts 400, 403, 411, 417, and 423 Medicare Program. January 28, 2005. Accessed at www.cms.hhs.gov/providerupdate/ regs/CMS4068F.pdf.
6. Bluml BM, McKenney JM, Cziraky MJ. Pharmaceutical care services and results in Project ImPACT: Hyperlipidemia. J Am Pharm Assoc. 2000;40:157-65.
7. Borgsdorf LR, Miano JS, Knapp KK. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm. 1994;51:772-7.
8. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in the United States Hospitals. Pharmacotherapy. 2000;20:609-21.
9. Jameson J, VanNoord G, Vanderwould K. The impact of a pharmacotherapy consultation on the cost and outcome of medical therapy. J Fam Pract. 1995;41:469-72.
10. Galt KA. Cost avoidance, acceptance, and outcomes associated with a pharmacotherapy consult clinic in a Veterans Affairs medical center. Pharmacotherapy. 1998;18:1103-11.
11. Lipton HL, Bero LA, Bird JA, et al. The impact of clinical pharmacists' consultations on physicians' geriatric drug prescribing. Med Care. 1992; 30:646-58.
12. Christensen D, Trygstad T, Sullivan R, et al. A pharmacy management intervention for optimizing drug therapy for nursing home patients. Am J Geriatr Pharmacother. 2004;2:248-56.
13. Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23:113-32.
14. Gurwich EL Comparison of medication histories acquired by pharmacists and physicians. Am J Hosp Pharm. 1983;40:1541-2.
15. Rovers J, Currie J, Hagel H, et al. Patient care plan development. In: A practical guide to pharmaceutical care. Washington, D.C.: American Pharmaceutical Association; 1998:77-102.
16. United Kingdom National Health Service. Pharmaceutical services regulations. 2005. Accessed at www.psnc.org.uk/index.php?type=page&pid= 67&k=11.
17. Rupp MT. Value of community pharmacists' interventions to correct prescribing errors. Ann Pharmacother. 1992;26:1580-4.
18. McMullin ST, Hennenfent JA, Ritchie D, et al. A prospective randomized trial to assess the cost impact of pharmacist-initiated interventions. Arch Intern Med. 1999;159:2306-9.
19. Knapp KK, Katzman H, Hambright JS, et al. Community pharmacist interventions in a capitated pharmacy benefit contract. Am J Health Syst Pharm. 1998;55:1141-5.
20. Dobie RL, Rascati KL. Documenting the value of pharmacist interventions. Am Pharm. 1994; NS34(5):50-4.
21. Rovers J, Currie J, Hagel H, et al. Documentation. In: A practical guide to pharmaceutical care. Washington, D.C.: American Pharmaceutical Association; 1998:103-18.
22. Currie JD, Doucette WR, Kuhle J, et al. Identification of essential elements in the documentation of pharmacist-provided care. J Am Pharm Assoc. 2003;43:41-9.